Immunohistochemical evaluation of estrogen and progesterone receptors of pre and post-neoadjuvant chemotherapy for breast cancer;Avaliação imunoistoquímica dos receptores de estrogênio e progesterona no câncer de mama, pré e pós-quimioterapia neoadjuvante

Revista do Colegio Brasileiro de Cirurgioes

Volumn 39, Issue 2, 2012, Pages 86-91

  Pachnick, Jan Pawel Andrade ^a   Czeczko, Nicolau Gregori ^a   Tuon, Filipe ^a   Cavalcanti, Tereza Santos ^a   Malafaia, Andressa Bressan ^a   Tuleski, Ana Maria ^a  

^a Evangelical University Hospital of Curitiba   (Brazil)

Author keywords

Colitis; Colon; Computer assisted; Fatty acids; Image processing; Volatile

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84864754387     PISSN: 01006991     EISSN: 18094546     Source Type: Journal    
DOI: 10.1590/S0100-69912012000200002     Document Type: Article

References (18)

1. Orvieto E, Viale G. Receptores dos hormônios esteroides. In: Veronesi U. Mastologia Oncológica. Rio de Janeiro: Medsi; 2002. p. 267-71.
2. Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, et al. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre-and post-neoadjuvant chemotherapy. Breast. 2008;17(5):523-7.
3. Shimizu C, Ando M, Kouno T, Katsumata N, Fujiwara Y. Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer. Jpn J Clin Oncol. 2007;37(1):1-8.
4. Depes DB, Souza MA, Ribalta JCL, Alves MTS, Kemp C, Lima GR. Alterações na expressão do antígeno nuclear de proliferação celular e dos receptores de estrogênio e de progesterona provocadas pela quimioterapia primária no carcinoma de mama. Rev Bras Ginecol Obst. 2003;25(8):545-52.
5. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003;88(3):406-12.
6. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133-44. Erratum in: Ann Oncol. 2007;18(11):1917.
7. Coradini D, Daidone MG. Biomolecular prognostic factors in breast cancer. Curr Opin Obstet Gynecol. 2004;16(1):49-55.
8. Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, et al. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res. 2008;10(3):R45.
9. Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. Breast J. 2008;14(2):141-6.
10. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380-8.
11. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer. 2003;10(1):91-8.
12. Katzenellenbogen BS, Norman MJ. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology. 1990;126(2):891-8.
13. Choi UJ, Lee KM. The changes of the histologic and biologic markers induced by neoadjuvant chemotherapy in locally advanced breast cancer. J Breast Cancer. 2009;12(1):41-6.
14. Hensel M, Schneeweiss A, Sinn HP, Egerer G, Kornacker M, Solomayer E, et al. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support. Stem Cells. 2002;20(1):32-40.
15. Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, et al. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Zentralbl Gynakol. 2006;128(2):76-81.
16. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92(1):147-55.
17. Bao H, Yu D, Wang J, Qiu T, Yang J, Wang L. Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients. Anticancer Drugs. 2008;19(3):317-23.
18. Ha GW, Youn HJ, Jung SH. The effect of neoadjuvant chemotherapy on the biological prognostic markers in breast cancer patients. J Korean Surg Soc. 2008;74(6):412-7.